Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP

Mondello, Patrizia; Mian, Michael

doi:10.1002/hon.2613

Cited by 37 publications

(21 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus far, the use of the R-CHOP regimen (including rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) as a standard component of immunochemotherapy has greatly improved the prognosis of patients with DLBCL, with a response rate of ~80% (5). However, some patients with DLBCL do not respond to the R-CHOP treatment due to disease heterogeneity (6). Thus, alternative or supplemental strategies are required for these subsets of patients with DLBCL.…”

Section: Introductionmentioning

confidence: 99%

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway

et al. 2021

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignant tumor type, and epigenetic modifications such as acetylation or deacetylation serve vital roles in its development. Chidamide, a novel histone deacetylase inhibitor, exerts an anticancer effect against various types of cancer. The present study aimed to evaluate the cellular effect of chidamide on a number of DLBCL cell lines and to investigate its underlying mechanism. The results demonstrated that chidamide induced the death of these cells in a concentration-(0-30 µmol/l) and time-dependent (24-72 h) manner, as determined using the Cell Counting Kit-8 cell viability assay. Moreover, chidamide promoted cellular apoptosis, which was identified via flow cytometry and western blot analysis, with an increase in cleaved caspase-3 expression and a decrease in Bcl-2 expression. Chidamide treatment also decreased the expression level of STAT3 and its phosphorylation, which was accompanied by the downregulation of a class-I histone deacetylase (HDAC) inhibitor, chidamide. Collectively, these data suggested that chidamide can be a potent therapeutic agent to treat DLBCL by inducing the apoptotic death of DLBCL cells by inhibiting the HDACs/STAT3/Bcl-2 pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Activated BCR leads to LYN kinase mediated cascade, and succeeding proteins such as SYK, BTK, and the CARD11-BCL10-MALT1 complex were activated. Subsequently, NF-κB free from IKK induces proliferative and antiapoptotic gene expression [5,66,67]. The schematic diagrams of cell cycle-and apoptosis-related factors are elucidated in Figures 1 and 2, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Conventional therapies including radiotherapy, chemotherapy, and combination therapy can be recommended and in case of indolent lymphoma, careful observation can be used [1]. Although conventional therapies have stridden forward over recent decades, it is still a noncurable disease, and its treatment has several side effects [5]. This is why new drugs for lymphoma need to be developed soon.…”

Section: Lymphomamentioning

confidence: 99%

Review of Natural Compounds for the Management and Prevention of Lymphoma

et al. 2020

View full text Add to dashboard Cite

Lymphoma is a type of blood cancer that can be categorized into two types-Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL). A total of 509,590 and 79,990 cases of NHL and HL were newly diagnosed in 2018, respectively. Although conventional therapy has stridden forward over recent decades, its adverse effects are still a hurdle to be solved. Thus, to help researchers develop better lymphoma treatment, this study aims to review the systematic anticancer data for natural products and their compounds. A variety of natural products showed anticancerous effects on lymphoma by regulation of intracellular mechanisms including apoptosis as well as cell cycle arrest. As these results shed light on the potential to substitute conventional therapy with natural products, it may become a promising strategy for lymphoma treatment in the near future.

show abstract

“…In the last years, the clinical management of patients with malignant lymphoma has benefited from research on tumour genomics and biology, particularly in the context of monoclonal antibodies and small molecule inhibitors [53,[103][104][105][106], despite some disappointing results of phase II/III trials on some promising agents (e.g., obinutuzumab and bortezomib) [107] for which the underlying mechanisms are not well understood. Moreover, a problem of the first line studies is that in relapsed setting drugs have a short duration of responses and no plateau.…”

Section: Discovering Personalized Treatment Approachesmentioning

confidence: 99%

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Coccaro

Anelli

Zagaria

et al. 2020

Cancers

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL.

show abstract

Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP

Cited by 37 publications

References 102 publications

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway

Review of Natural Compounds for the Management and Prevention of Lymphoma

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Contact Info

Product

Resources

About